Concepts (274)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 19 | 2007 | 324 | 1.060 |
Why?
|
| Islets of Langerhans Transplantation | 21 | 2006 | 179 | 0.970 |
Why?
|
| Pancreas Transplantation | 7 | 2007 | 19 | 0.760 |
Why?
|
| Graft Survival | 13 | 2007 | 296 | 0.750 |
Why?
|
| Leukocyte Common Antigens | 10 | 2006 | 58 | 0.740 |
Why?
|
| Plasma Gases | 4 | 2022 | 4 | 0.720 |
Why?
|
| Graft Rejection | 9 | 2004 | 302 | 0.490 |
Why?
|
| Diabetes Mellitus, Experimental | 5 | 2018 | 206 | 0.380 |
Why?
|
| Bandages | 1 | 2012 | 16 | 0.370 |
Why?
|
| Antibodies, Monoclonal | 7 | 2006 | 875 | 0.370 |
Why?
|
| Hemostatics | 1 | 2012 | 27 | 0.360 |
Why?
|
| Warfare | 1 | 2012 | 42 | 0.360 |
Why?
|
| Tissue Donors | 8 | 2007 | 146 | 0.340 |
Why?
|
| Islets of Langerhans | 12 | 2006 | 286 | 0.340 |
Why?
|
| Military Personnel | 1 | 2012 | 109 | 0.330 |
Why?
|
| Hemorrhage | 1 | 2012 | 285 | 0.320 |
Why?
|
| Tissue and Organ Procurement | 4 | 2007 | 39 | 0.300 |
Why?
|
| Wounds and Injuries | 1 | 2012 | 250 | 0.300 |
Why?
|
| Ursidae | 2 | 2020 | 12 | 0.290 |
Why?
|
| Transplantation Tolerance | 3 | 2006 | 69 | 0.270 |
Why?
|
| CD40 Ligand | 4 | 2005 | 158 | 0.270 |
Why?
|
| Transplantation Immunology | 4 | 2005 | 26 | 0.240 |
Why?
|
| Transplantation, Homologous | 10 | 2006 | 250 | 0.220 |
Why?
|
| Bacterial Infections | 2 | 2004 | 150 | 0.210 |
Why?
|
| Immunosuppressive Agents | 6 | 2001 | 380 | 0.210 |
Why?
|
| Neoplasm Proteins | 2 | 2021 | 285 | 0.200 |
Why?
|
| Aspergillosis | 1 | 2003 | 35 | 0.200 |
Why?
|
| Osteomyelitis | 1 | 2003 | 24 | 0.200 |
Why?
|
| Spinal Diseases | 1 | 2003 | 50 | 0.200 |
Why?
|
| Hibernation | 2 | 2020 | 10 | 0.200 |
Why?
|
| Insulin | 10 | 2005 | 695 | 0.200 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 1222 | 0.190 |
Why?
|
| Sarcoma | 1 | 2022 | 36 | 0.180 |
Why?
|
| Mice, Inbred BALB C | 9 | 2006 | 869 | 0.180 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2022 | 32 | 0.180 |
Why?
|
| RNA, Neoplasm | 1 | 2021 | 36 | 0.170 |
Why?
|
| Cholangiocarcinoma | 1 | 2021 | 35 | 0.170 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2022 | 71 | 0.170 |
Why?
|
| Antibodies, Blocking | 1 | 2001 | 39 | 0.170 |
Why?
|
| Antigens, Differentiation | 4 | 2006 | 144 | 0.160 |
Why?
|
| Hemostasis | 1 | 2020 | 19 | 0.160 |
Why?
|
| Chorion | 1 | 2018 | 5 | 0.140 |
Why?
|
| Amnion | 1 | 2018 | 9 | 0.140 |
Why?
|
| Achilles Tendon | 1 | 2018 | 8 | 0.140 |
Why?
|
| Diabetic Nephropathies | 2 | 2004 | 37 | 0.140 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 150 | 0.140 |
Why?
|
| Tendon Injuries | 1 | 2018 | 16 | 0.140 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2018 | 42 | 0.140 |
Why?
|
| Histones | 1 | 2021 | 494 | 0.140 |
Why?
|
| Animals | 27 | 2020 | 21333 | 0.130 |
Why?
|
| Antibodies | 1 | 1998 | 187 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 464 | 0.130 |
Why?
|
| Blood Coagulation | 1 | 2017 | 41 | 0.130 |
Why?
|
| Body Constitution | 1 | 1997 | 16 | 0.130 |
Why?
|
| Histocompatibility Testing | 1 | 1997 | 32 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 10 | 2006 | 3481 | 0.130 |
Why?
|
| Immune Tolerance | 3 | 2005 | 181 | 0.130 |
Why?
|
| RNA, Messenger | 2 | 2021 | 1575 | 0.120 |
Why?
|
| Osteoporosis | 3 | 2002 | 113 | 0.120 |
Why?
|
| Humans | 31 | 2022 | 65141 | 0.120 |
Why?
|
| Immunotherapy | 1 | 1998 | 274 | 0.110 |
Why?
|
| Kidney | 2 | 1997 | 451 | 0.110 |
Why?
|
| Immunoglobulins | 1 | 1994 | 74 | 0.110 |
Why?
|
| Immunization, Passive | 1 | 1994 | 96 | 0.110 |
Why?
|
| Cytomegalovirus Infections | 1 | 1994 | 68 | 0.100 |
Why?
|
| Mice | 14 | 2006 | 11114 | 0.100 |
Why?
|
| Cytomegalovirus | 1 | 1994 | 94 | 0.100 |
Why?
|
| Incidence | 5 | 2004 | 1419 | 0.100 |
Why?
|
| MicroRNAs | 1 | 2020 | 710 | 0.100 |
Why?
|
| Ischemia | 1 | 1995 | 203 | 0.100 |
Why?
|
| Time Factors | 8 | 2006 | 3762 | 0.100 |
Why?
|
| RNA, Small Interfering | 3 | 2022 | 983 | 0.100 |
Why?
|
| Male | 19 | 2020 | 31055 | 0.100 |
Why?
|
| Heart Arrest | 1 | 1995 | 175 | 0.100 |
Why?
|
| Signal Transduction | 3 | 2003 | 3149 | 0.090 |
Why?
|
| Cell Line, Tumor | 3 | 2021 | 1566 | 0.090 |
Why?
|
| Cyclosporins | 4 | 1987 | 17 | 0.080 |
Why?
|
| Postoperative Complications | 3 | 2002 | 1322 | 0.080 |
Why?
|
| Adjuvants, Immunologic | 2 | 2003 | 235 | 0.080 |
Why?
|
| Cell Death | 2 | 2022 | 289 | 0.080 |
Why?
|
| Gene Silencing | 2 | 2020 | 433 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 373 | 0.080 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2007 | 30 | 0.080 |
Why?
|
| Antigens | 2 | 2006 | 145 | 0.070 |
Why?
|
| Apoptosis | 2 | 2022 | 1100 | 0.070 |
Why?
|
| Seasons | 2 | 2020 | 139 | 0.070 |
Why?
|
| Female | 13 | 2022 | 34030 | 0.070 |
Why?
|
| Antilymphocyte Serum | 3 | 1998 | 22 | 0.070 |
Why?
|
| Graft Enhancement, Immunologic | 2 | 2003 | 10 | 0.070 |
Why?
|
| Health Care Rationing | 1 | 2007 | 21 | 0.060 |
Why?
|
| Organ Transplantation | 1 | 2007 | 46 | 0.060 |
Why?
|
| Acyclovir | 2 | 1997 | 20 | 0.060 |
Why?
|
| Death | 1 | 2006 | 33 | 0.060 |
Why?
|
| Guidelines as Topic | 1 | 2007 | 158 | 0.060 |
Why?
|
| Spleen | 2 | 1986 | 474 | 0.060 |
Why?
|
| Up-Regulation | 3 | 2020 | 374 | 0.060 |
Why?
|
| Middle Aged | 10 | 2007 | 18273 | 0.060 |
Why?
|
| Skin Transplantation | 3 | 2005 | 154 | 0.060 |
Why?
|
| Reoperation | 1 | 2007 | 301 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2006 | 116 | 0.060 |
Why?
|
| Rats | 4 | 2018 | 1994 | 0.060 |
Why?
|
| Antigens, CD | 5 | 2006 | 342 | 0.060 |
Why?
|
| Bone Diseases, Metabolic | 2 | 2002 | 20 | 0.060 |
Why?
|
| Retrospective Studies | 6 | 1997 | 6865 | 0.050 |
Why?
|
| Immunoconjugates | 2 | 2003 | 95 | 0.050 |
Why?
|
| CTLA-4 Antigen | 4 | 2006 | 72 | 0.050 |
Why?
|
| Dogs | 6 | 1986 | 315 | 0.050 |
Why?
|
| Diabetes Mellitus | 2 | 2006 | 555 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2005 | 675 | 0.050 |
Why?
|
| Kidney Failure, Chronic | 1 | 2004 | 196 | 0.050 |
Why?
|
| Cell Separation | 1 | 2002 | 147 | 0.050 |
Why?
|
| Alendronate | 1 | 2002 | 14 | 0.040 |
Why?
|
| Blood Glucose | 4 | 1997 | 497 | 0.040 |
Why?
|
| Chronic Disease | 2 | 1997 | 742 | 0.040 |
Why?
|
| Receptors, Progesterone | 1 | 2022 | 110 | 0.040 |
Why?
|
| Living Donors | 2 | 2004 | 79 | 0.040 |
Why?
|
| Leucovorin | 1 | 2021 | 8 | 0.040 |
Why?
|
| Bone Remodeling | 1 | 2001 | 25 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2022 | 130 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2021 | 68 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2021 | 142 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2002 | 2484 | 0.040 |
Why?
|
| Adult | 8 | 2006 | 17358 | 0.040 |
Why?
|
| Cell Division | 1 | 2022 | 449 | 0.040 |
Why?
|
| Models, Immunological | 1 | 2001 | 85 | 0.040 |
Why?
|
| Antithrombin III | 1 | 2020 | 15 | 0.040 |
Why?
|
| Bone Resorption | 1 | 2000 | 46 | 0.040 |
Why?
|
| Muromonab-CD3 | 2 | 1997 | 7 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 2021 | 325 | 0.040 |
Why?
|
| Injections, Intravenous | 3 | 2005 | 159 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2001 | 202 | 0.040 |
Why?
|
| Infection Control | 1 | 2001 | 104 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2001 | 268 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2001 | 463 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 856 | 0.040 |
Why?
|
| Cadaver | 2 | 2004 | 127 | 0.040 |
Why?
|
| Rupture | 1 | 2018 | 24 | 0.040 |
Why?
|
| Hepatocytes | 1 | 2020 | 222 | 0.040 |
Why?
|
| Cell Movement | 1 | 2001 | 480 | 0.040 |
Why?
|
| Monocytes | 1 | 2001 | 361 | 0.040 |
Why?
|
| Pancreatectomy | 4 | 1986 | 99 | 0.040 |
Why?
|
| Creatinine | 2 | 2002 | 135 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2001 | 563 | 0.030 |
Why?
|
| Ganciclovir | 1 | 1997 | 18 | 0.030 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1997 | 38 | 0.030 |
Why?
|
| Hospitalization | 2 | 1996 | 1392 | 0.030 |
Why?
|
| Osteocalcin | 3 | 2002 | 46 | 0.030 |
Why?
|
| Transplantation, Isogeneic | 1 | 1997 | 8 | 0.030 |
Why?
|
| Body Surface Area | 1 | 1997 | 11 | 0.030 |
Why?
|
| Tacrolimus | 1 | 1997 | 63 | 0.030 |
Why?
|
| Cyclosporine | 1 | 1997 | 77 | 0.030 |
Why?
|
| Cytokines | 1 | 2001 | 952 | 0.030 |
Why?
|
| Bone Density | 3 | 2002 | 142 | 0.030 |
Why?
|
| Fluid Therapy | 1 | 1996 | 46 | 0.030 |
Why?
|
| Exons | 1 | 1997 | 208 | 0.030 |
Why?
|
| Thymectomy | 2 | 2006 | 35 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 1997 | 199 | 0.030 |
Why?
|
| Regression Analysis | 1 | 1997 | 497 | 0.030 |
Why?
|
| Acute Disease | 2 | 1998 | 663 | 0.030 |
Why?
|
| Glucose Tolerance Test | 2 | 1986 | 97 | 0.030 |
Why?
|
| Waiting Lists | 2 | 2007 | 56 | 0.030 |
Why?
|
| Body Weight | 1 | 1997 | 376 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 1995 | 116 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 1997 | 321 | 0.030 |
Why?
|
| Opportunistic Infections | 1 | 1994 | 29 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 1997 | 930 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1994 | 34 | 0.030 |
Why?
|
| Temperature | 1 | 1995 | 316 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1995 | 624 | 0.030 |
Why?
|
| Kinetics | 1 | 1995 | 759 | 0.030 |
Why?
|
| Virus Diseases | 1 | 1994 | 117 | 0.030 |
Why?
|
| Actuarial Analysis | 1 | 1993 | 17 | 0.020 |
Why?
|
| Morbidity | 1 | 1993 | 110 | 0.020 |
Why?
|
| Abatacept | 2 | 2003 | 67 | 0.020 |
Why?
|
| Communicable Diseases | 1 | 1993 | 86 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2007 | 5790 | 0.020 |
Why?
|
| Survival Analysis | 1 | 1993 | 576 | 0.020 |
Why?
|
| Risk Factors | 2 | 2004 | 5430 | 0.020 |
Why?
|
| Age Factors | 2 | 2007 | 1585 | 0.020 |
Why?
|
| Transplantation, Autologous | 3 | 1986 | 128 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 2293 | 0.020 |
Why?
|
| Preoperative Care | 2 | 1996 | 199 | 0.020 |
Why?
|
| Mice, Inbred NOD | 2 | 2003 | 526 | 0.020 |
Why?
|
| Liver Transplantation | 2 | 2007 | 220 | 0.020 |
Why?
|
| Amino Acids | 2 | 2001 | 148 | 0.020 |
Why?
|
| Lymphocyte Activation | 2 | 2003 | 752 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2005 | 2156 | 0.020 |
Why?
|
| Length of Stay | 1 | 1993 | 827 | 0.020 |
Why?
|
| Calcium | 2 | 2002 | 584 | 0.020 |
Why?
|
| Cold Ischemia | 1 | 2007 | 3 | 0.020 |
Why?
|
| Lung Transplantation | 1 | 2007 | 74 | 0.020 |
Why?
|
| Glucose | 2 | 1986 | 476 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 1986 | 63 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2007 | 208 | 0.020 |
Why?
|
| Fasting | 1 | 1986 | 52 | 0.010 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2006 | 40 | 0.010 |
Why?
|
| Biomarkers | 2 | 2002 | 1480 | 0.010 |
Why?
|
| Methods | 1 | 2005 | 40 | 0.010 |
Why?
|
| Lymphocyte Transfusion | 1 | 2005 | 37 | 0.010 |
Why?
|
| Postoperative Care | 1 | 1986 | 125 | 0.010 |
Why?
|
| Isoantibodies | 1 | 2005 | 35 | 0.010 |
Why?
|
| Organ Preservation Solutions | 1 | 2005 | 5 | 0.010 |
Why?
|
| Raffinose | 1 | 2005 | 3 | 0.010 |
Why?
|
| Heart Transplantation | 1 | 2007 | 180 | 0.010 |
Why?
|
| Adolescent | 3 | 2004 | 6306 | 0.010 |
Why?
|
| Allopurinol | 1 | 2005 | 15 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1986 | 371 | 0.010 |
Why?
|
| Glutathione | 1 | 2005 | 55 | 0.010 |
Why?
|
| Models, Animal | 1 | 2005 | 241 | 0.010 |
Why?
|
| Adenosine | 1 | 2005 | 78 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2003 | 47 | 0.010 |
Why?
|
| New England | 1 | 2004 | 271 | 0.010 |
Why?
|
| Risk | 1 | 2004 | 374 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2006 | 351 | 0.010 |
Why?
|
| Coronary Disease | 1 | 2004 | 246 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 401 | 0.010 |
Why?
|
| Interleukin-7 | 1 | 2003 | 29 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2007 | 897 | 0.010 |
Why?
|
| CD3 Complex | 1 | 2003 | 63 | 0.010 |
Why?
|
| Ficoll | 1 | 2002 | 4 | 0.010 |
Why?
|
| Filtration | 1 | 2002 | 19 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 2003 | 166 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2006 | 1290 | 0.010 |
Why?
|
| Base Sequence | 1 | 2005 | 1329 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2003 | 164 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 2002 | 46 | 0.010 |
Why?
|
| Calcineurin Inhibitors | 1 | 2001 | 22 | 0.010 |
Why?
|
| Everolimus | 1 | 2001 | 22 | 0.010 |
Why?
|
| Cell Line | 1 | 2006 | 2023 | 0.010 |
Why?
|
| Algorithms | 1 | 2007 | 1048 | 0.010 |
Why?
|
| Infection Control Practitioners | 1 | 2001 | 2 | 0.010 |
Why?
|
| Facility Regulation and Control | 1 | 2001 | 3 | 0.010 |
Why?
|
| Professional Staff Committees | 1 | 2001 | 5 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2005 | 639 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 2001 | 47 | 0.010 |
Why?
|
| Physician Executives | 1 | 2001 | 28 | 0.010 |
Why?
|
| Italy | 1 | 2001 | 69 | 0.010 |
Why?
|
| Sirolimus | 1 | 2001 | 93 | 0.010 |
Why?
|
| Parathyroid Hormone | 1 | 2001 | 44 | 0.010 |
Why?
|
| Nursing Staff | 1 | 2001 | 40 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2003 | 574 | 0.010 |
Why?
|
| Prednisone | 1 | 2000 | 83 | 0.010 |
Why?
|
| Aged | 3 | 2004 | 14963 | 0.010 |
Why?
|
| Calcineurin | 1 | 2001 | 48 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2006 | 1630 | 0.010 |
Why?
|
| Hypertension | 1 | 2004 | 612 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 2005 | 839 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2004 | 2061 | 0.010 |
Why?
|
| Rabbits | 1 | 1998 | 338 | 0.010 |
Why?
|
| Antigens, CD19 | 1 | 1997 | 25 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2001 | 1282 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1997 | 194 | 0.010 |
Why?
|
| Rats, Inbred Lew | 2 | 1987 | 106 | 0.010 |
Why?
|
| Prognosis | 1 | 2001 | 1785 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1998 | 739 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1996 | 175 | 0.010 |
Why?
|
| Nephrectomy | 1 | 1996 | 92 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2001 | 1008 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2001 | 801 | 0.010 |
Why?
|
| Child | 1 | 2004 | 4612 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2001 | 3310 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2000 | 2704 | 0.010 |
Why?
|
| United States | 1 | 2007 | 8098 | 0.010 |
Why?
|
| Rats, Inbred ACI | 1 | 1987 | 6 | 0.000 |
Why?
|
| Rats, Inbred BN | 1 | 1987 | 27 | 0.000 |
Why?
|
| Methacholine Compounds | 1 | 1986 | 12 | 0.000 |
Why?
|
| Methacholine Chloride | 1 | 1986 | 23 | 0.000 |
Why?
|
| Vagus Nerve | 1 | 1986 | 20 | 0.000 |
Why?
|
| Portal Vein | 1 | 1986 | 39 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1987 | 254 | 0.000 |
Why?
|
| Electric Stimulation | 1 | 1986 | 139 | 0.000 |
Why?
|
| Combined Modality Therapy | 1 | 1987 | 372 | 0.000 |
Why?
|
| Tissue Preservation | 1 | 1985 | 5 | 0.000 |
Why?
|
| Swine | 1 | 1985 | 394 | 0.000 |
Why?
|